Most Read Articles
Pearl Toh, 4 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 6 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Very low BMI at discharge ups mortality risk in patients with ADHF

13 Oct 2020
The Health Sciences Authority has given the green light for a novel combination drug for adults with symptomatic chronic heart failure.

Being discharged with a very low body mass index (BMI) worsens survival outlook in patients with acute decompensated heart failure (ADHF), reports a recent Japan study.

Researchers enrolled 3,509 ADHF patients who were divided into five groups according to discharge BMI: severely underweight (BMI <16 kg/m2), underweight (BMI ≥16 to <18.5 kg/m2), normal (BMI ≥18.5 to <25 kg/m2), overweight (BMI, ≥25 to <30 kg/m2), and obese (BMI ≥30 kg/m2). Outcomes include all-cause death after discharge, cardiovascular and non-cardiovascular deaths, and HF hospitalizations.

The cumulative 1-year incidence rate of all-cause deaths was highest in severely underweight (36.3 percent) patients and lowest in those who were overweight (7.9 percent). There was a significant difference among the Kaplan-Meier survival curves of all groups (log-rank p<0.001).

Adjusting for confounders revealed that being severely underweight (hazard ratio [HR], 2.32, 95 percent confidence interval [CI], 1.83–2.94; p<0.001) and underweight (HR, 1.31, 95 percent CI, 1.08–1.59; p=0.005) were significant risk factors for all-cause mortality, as compared to normal BMI. Being overweight or obese had no such effects.

Similarly, the risk of cardiovascular death (HR, 2.23, 95 percent CI, 1.64–3.03; p<0.001) and non-cardiovascular deaths (HR, 2.43, 95 percent CI, 1.67–3.54; p<0.001), but not HF hospitalizations, were significantly elevated in patients who were severely underweight at discharge. For all three outcomes, being overweight or obese had no meaningful impact.

The principal findings remained largely unchanged even when researchers instead changed the BMI cutoff values to the standards used for Asian populations.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 4 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 6 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.